All News

Real-time text check-ins helped physicians identify issues sooner and support quality of life for patients with myeloma at ASH 2025.

Among patients with previously untreated diffuse large B-cell lymphoma, odronextamab has been associated with early efficacy.

In patients with R/R multiple myeloma, real-world Elrexfio was associated with shorter time until progression but higher rates of response than Tecvayli.

Venclexta regimens showed comparable progression-free survival versus continuous Imbruvica.

For pediatric and young adult patients with B-cell acute lymphoblastic leukemia, removal of total body irradiation did not compromise efficacy.

Among children receiving chemotherapy for acute lymphoblastic leukemia, 30% of their families developed catastrophic financial toxicity.

CURE honored four individuals whose compassion and leadership shaped support education and empowerment for people living with blood cancers.

I believe time to be a gift, and as such, my sister was gifted more than a decade despite a terminal illness, and I do have gratitude for that.

Dr. Thomas Marron explains how therapeutic vaccines differ from preventative vaccines in lung cancer care.

Facing my cancer diagnosis, I learned it’s okay not to be okay and found comfort in laughter, honesty, and the support of loved ones.

Dr. Ajay Gupta of the Roswell Park Comprehensive Cancer Center discussed basics of gastrointestinal stromal tumors.

TARA-002 may offer meaningful benefits for patients with non-muscle invasive bladder cancer, including those who have limited treatment options.

Dr. Daniel Peters discussed targeted therapies and regimens that patients with acute myeloid leukemia, or AML, should be aware of.

The FDA approved Breyanzi for adults with relapsed or refractory marginal zone lymphoma who received at least two prior lines of systemic therapy.

I’ve lived with stage 4 breast cancer for 11 years, and each day brings gratitude for my family, my oncologist, and the care that keeps me going.

Stage 1 myelofibrosis is a manageable early-stage blood cancer that requires ongoing monitoring and personalized care to support long-term health.

As part of her journey with stage 3 inflammatory breast cancer, Lindsey Gunter experienced chemotherapy side effects so severe that she was unable to walk.

I experienced acute myeloid leukemia twice. Had it not been for follow up appointments I would not be here.

This guide explains how squamous cell lung cancer is diagnosed and treated at each stage to help patients talk openly with their oncology team.

The U.S. commercial launch of LYMPHIR offers a new treatment option for patients with relapsed/refractory stage 1 to 3 cutaneous T-cell lymphoma.

Dr. Girindra Raval sat down for an interview with CURE to discuss what patients with EGFR-mutated lung cancer should know about their treatment options.

I share how my sister’s final days felt different from her many rebounds and how I continue to process the grief of losing her after years of anticipation.

Nona Baker, who was first diagnosed with a blood cancer in 1991, shares her experience with polycythemia vera.

In November 2025, the FDA issued multiple oncology approvals that expanded treatment access for patients with breast, lung, blood and solid tumor cancers.

The FDA granted traditional approval to Jaypirca for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Dr. Charles M. Rudin discussed recent treatment advancements for patients with small cell lung cancer.

IGV-001 improved survival for newly diagnosed glioblastoma in a phase 2b trial, with patients living a median 20.3 months and no serious safety issues.

I found purpose again after my myeloma diagnosis when I returned to teaching and shared my work, moments that reminded me I could still grow and reconnect.